ESTRO 2025 - Abstract Book

S846

Clinical - Gynaecology

ESTRO 2025

Results:

Of the 353 patients, 56.4% (n=199) received adjuvant radiotherapy, while 43.6% (n=154) underwent surgery alone. The addition of radiotherapy improved 5-year local control rates (94.5% vs. 80.2%, p < 0.05) and was associated with higher DFS at 5 years (92.3% vs. 81.1%, p < 0.05). CSS at 5 years was also significantly improved in patients receiving radiotherapy (73.4% vs. 63.8%). OS at 5 years was comparable between groups (53.7% vs. 48.1%, p > 0.05), likely reflecting the influence of non-cancer mortality in this elderly population. Chronic gastrointestinal and genitourinary toxicity of grade ≥3 was observed in 4.7% (n=16) of patients receiving radiotherapy (3.1% gastrointestinal and 1.6% genitourinary toxicity). Importantly, no grade ≥3 toxicities were recorded in patients treated with surgery alone. Conclusion: Adjuvant radiotherapy significantly improved local control and disease-free survival in patients aged ≥80 years with endometrial cancer, without substantial increases in high-grade chronic toxicity. These findings underscore the value of radiotherapy as part of a multidisciplinary treatment approach in elderly patients, particularly those with risk factors for recurrence. Future prospective studies are needed to refine patient selection and integrate molecular biomarkers into clinical decision-making.

Keywords: Elderly, Endometrial Cancer, Radiotherapy